Evidence map›Paper›PMID 42304303›Full record

Trial reportBMC neurology2026

Efficacy and safety of

Ronghua Hong, Zhuang Wu, Sha Zhu, Lizhen Pan, Yougui Pan, Xiaolong Zhang, Shuzhen Chen, Qiang Guan, Lingjing Jin

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ronghua Hong *Department of Neurology and Neurological Rehabilitation, Shanghai Disabled Persons' Federation Key Laboratory of Intelligent Rehabilitation Assistive Devices and Technologies, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, 2209 Guangxing Road, Shanghai, 201619, China.
Zhuang Wu *Neurotoxin Research Center, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200065, China.
Sha ZhuDepartment of Neurology and Neurological Rehabilitation, Shanghai Disabled Persons' Federation Key Laboratory of Intelligent Rehabilitation Assistive Devices and Technologies, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, 2209 Guangxing Road, Shanghai, 201619, China.
Lizhen PanNeurotoxin Research Center, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200065, China.
Yougui PanNeurotoxin Research Center, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200065, China.
Xiaolong ZhangNeurotoxin Research Center, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200065, China.
Shuzhen ChenDepartment of Nuclear Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Qiang GuanNeurotoxin Research Center, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200065, China. guanqianglu@126.com.
Lingjing JinDepartment of Neurology and Neurological Rehabilitation, Shanghai Disabled Persons' Federation Key Laboratory of Intelligent Rehabilitation Assistive Devices and Technologies, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, 2209 Guangxing Road, Shanghai, 201619, China. lingjingjin@tongji.edu.cn.ORCID http://orcid.org/0000-0001-7199-2578

Funding

Clinical Technology Innovation Project of Shanghai Shenkang Hospital Development Center SHDC12020119National Clinical Key Specialty Construction Project of China Z155080000004Science and Technology Innovation Program of Shanghai Municipal Science and Technology 22Y31900200 and 22Y31900203Shanghai Clinical Research Ward SHDC2023CRW018BShanghai Hospital Development Center Foundation-Shanghai Municipal Hospital Rehabilitation Medicine Specialty Alliance SHDC22023304Shanghai Municipal Science and Technology Commission Rising Star Program 24YF2740400Shanghai Rehabilitation Medical Research Center (Top Priority Research Center of Shanghai) 2023ZZ02027the National Key Research and Development Program 2023YFC3604500/2023YFC3604505the National Natural Science Foundation of China 82230084 and 82172545the National Natural Science Foundation of China 82503060
6 · The paper itself

Abstract

backgroundTechnetium-sestamibi single-photon emission computed tomography (

methodsEligible PD patients with postural abnormalities all underwent

resultsA total of 29 PD patients (14 males, 15 females) were analyzed with a mean age of 68.5 ± 8.9 years. The RTF increased (37.71 ± 16.82° vs. 40.17 ± 17.03°, Estimated Mean Difference = -2.46, 95% CI [-5.97, 1.06], p = 0.027) significantly while the RTL decreased (9.61 ± 8.78° vs. 8.28 ± 7.62°, Estimated Mean Difference = 1.34, 95% CI [-0.99, 3.67], p = 0.208) slightly at 1 month compared to baseline, though the difference was not significant. At 1 month, 4 patients (13.8%) experienced an improvement of more than 5° in RTF, 13 patients (44.8%) reported minimal to much subjective improvement and 10 patients (34.5%) saw an improvement of more than 1 point in the pain VAS score. Eleven AEs occurred, with no serious adverse events (SAEs). Related AEs mainly included transient worsening of postural abnormalities and low-back pain, which typically alleviated within 2 weeks to 2 months.

conclusionsThe CLINICAL TRIALS REGISTRATION: the Chinese Clinical Trial Registry, number ChiCTR2000039775, Nov. 8th, 2020.

Indexed as

Botulinum ToxinsParkinson DiseaseTechnetium Tc 99m SestamibiTomography, Emission-Computed, Single-PhotonAgedFemaleHumansMaleMiddle AgedRadiopharmaceuticalsTreatment OutcomeBotulinum ToxinsRadiopharmaceuticalsTechnetium Tc 99m Sestamibi99mTc-MIBI SPECTBotulinum toxinParkinson’s diseasePostural abnormalities

Identifiers

PMID42304303
PMCPMC13508259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.